CCR1 and glomerular disorder: Rather than global CCL5 inhibition, selective CCR1/CCR5 antagonism in macrophages may preserve the podocyte-protective effects of CCL5 while mitigating its proinflammatory activity, offering a more refined therapeutic strategy for glomerular disease.